安进公司股价周三盘中大涨5.05%,引起了市场的广泛关注。
根据新闻报道,此次股价大涨的主要原因包括:
1)公司2024年财报出炉,全年总收入达到334.24亿美元,同比增长19%,增长动能强劲。其中多款块旦增长迅猛,如降脂药物Repatha突破22亿美元,骨质疏松症领域拳头产品地舒单抗合计收入近66亿美元。
2)罕见病、炎症和肿瘤等多个板块的新产品贡献力量不断提升。如罕见病领域三大药物Tepezza、Krystexxa和Uplizna销售业绩加速放量,抗炎药物Tezspire完成重要里程碑,肿瘤产品Lumykras/Lumykras和Imdelltra开局不错。
3)公司研发管线丰富,未来多达十余款新产品有望取得关键进展。包括于今年下半年推进肥胖症单抗AMG 133至III期,Tezspire两项新适应症III期完成/启动,Imdelltra在小细胞肺癌多项适应症III期结果出炉等。
4)公司对2025年业绩持乐观态度,给出了343-357亿美元的营收预期。预计今年将迎来产品爆发期,产品管线推动公司持续快速增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.